['ANTIARRHYTHMICS: AMIODARONE, BEPRIDIL, PROPAFENONE, QUINIDINE', '\xe2\x86\x91 ANTIARRHYTHMICS', 'COADMINISTRATION WITH VICTRELIS HAS THE POTENTIAL TO PRODUCE SERIOUS AND/OR LIFE-THREATENING ADVERSE EVENTS AND HAS NOT BEEN STUDIED. CAUTION IS WARRANTED AND THERAPEUTIC CONCENTRATION MONITORING OF THESE DRUGS IS RECOMMENDED IF THEY ARE USED CONCOMITANTLY WITH VICTRELIS.', 'DIGOXIN', '\xe2\x86\x91 DIGOXIN', 'DIGOXIN CONCENTRATIONS INCREASED WHEN ADMINISTERED WITH VICTRELIS [SEE CLINICAL PHARMACOLOGY (12.3) ] . MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING VICTRELIS. CONTINUE MONITORING DIGOXIN CONCENTRATIONS; CONSULT THE DIGOXIN PRESCRIBING INFORMATION FOR INFORMATION ON TITRATING THE DIGOXIN DOSE.', 'ANTICOAGULANT: WARFARIN', '\xe2\x86\x91 OR \xe2\x86\x93 WARFARIN', 'CONCENTRATIONS OF WARFARIN MAY BE ALTERED WHEN CO-ADMINISTERED WITH VICTRELIS. MONITOR INR CLOSELY.', 'ANTIDEPRESSANTS: TRAZODONE, DESIPRAMINE', '\xe2\x86\x91 TRAZODONE \xe2\x86\x91 DESIPRAMINE', 'PLASMA CONCENTRATIONS OF TRAZODONE AND DESIPRAMINE MAY INCREASE WHEN ADMINISTERED WITH VICTRELIS, RESULTING IN ADVERSE EVENTS SUCH AS DIZZINESS, HYPOTENSION AND SYNCOPE. USE WITH CAUTION AND CONSIDER A LOWER DOSE OF TRAZODONE OR DESIPRAMINE.', 'ESCITALOPRAM', '\xe2\x86\x93ESCITALOPRAM', 'EXPOSURE OF ESCITALOPRAM WAS SLIGHTLY DECREASED WHEN COADMINISTERED WITH VICTRELIS. SELECTIVE SEROTONIN REUPTAKE INHIBITORS SUCH AS ESCITALOPRAM HAVE A WIDE THERAPEUTIC INDEX, BUT DOSES MAY NEED TO BE ADJUSTED WHEN COMBINED WITH VICTRELIS.', 'ANTIFUNGALS: KETOCONAZOLE THESE COMBINATIONS HAVE BEEN STUDIED; SEE CLINICAL PHARMACOLOGY (12.3) FOR MAGNITUDE OF INTERACTION. , ITRACONAZOLE, POSACONAZOLE, VORICONAZOLE', '\xe2\x86\x91 BOCEPREVIR \xe2\x86\x91 ITRACONAZOLE \xe2\x86\x91 KETOCONAZOLE \xe2\x86\x91 POSACONAZOLE \xe2\x86\x91 VORICONAZOLE', 'PLASMA CONCENTRATIONS OF KETOCONAZOLE, ITRACONAZOLE, VORICONAZOLE OR POSACONAZOLE MAY BE INCREASED WITH VICTRELIS. WHEN COADMINISTRATION IS REQUIRED, DOSES OF KETOCONAZOLE AND ITRACONAZOLE SHOULD NOT EXCEED 200 MG/DAY.', 'ANTI-GOUT: COLCHICINE', '\xe2\x86\x91 COLCHICINE', 'SIGNIFICANT INCREASES IN COLCHICINE LEVELS ARE EXPECTED; FATAL COLCHICINE TOXICITY HAS BEEN REPORTED WITH OTHER STRONG CYP3A4 INHIBITORS. PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT SHOULD NOT BE GIVEN COLCHICINE WITH VICTRELIS. TREATMENT OF GOUT FLARES (DURING TREATMENT WITH VICTRELIS): 0.6 MG (1 TABLET) \xc3\x97 1 DOSE, FOLLOWED BY 0.3 MG (HALF TABLET) 1 HOUR LATER. DOSE TO BE REPEATED NO EARLIER THAN 3 DAYS. PROPHYLAXIS OF GOUT FLARES (DURING TREATMENT WITH VICTRELIS): IF THE ORIGINAL REGIMEN WAS 0.6 MG TWICE A DAY, REDUCE DOSE TO 0.3 MG ONCE A DAY. IF THE ORIGINAL REGIMEN WAS 0.6 MG ONCE A DAY, REDUCE THE DOSE TO 0.3 MG ONCE EVERY OTHER DAY. TREATMENT OF FAMILIAL MEDITERRANEAN FEVER (FMF) (DURING TREATMENT WITH VICTRELIS): MAXIMUM DAILY DOSE OF 0.6 MG (MAY BE GIVEN AS 0.3 MG TWICE A DAY).', 'ANTI-INFECTIVE: CLARITHROMYCIN', '\xe2\x86\x91 CLARITHROMYCIN', 'CONCENTRATIONS OF CLARITHROMYCIN MAY BE INCREASED WITH VICTRELIS; HOWEVER, NO DOSAGE ADJUSTMENT IS NECESSARY FOR PATIENTS WITH NORMAL RENAL FUNCTION.', 'ANTIMYCOBACTERIAL: RIFABUTIN', '\xe2\x86\x93 BOCEPREVIR \xe2\x86\x91 RIFABUTIN', 'INCREASES IN RIFABUTIN EXPOSURE ARE ANTICIPATED, WHILE EXPOSURE OF BOCEPREVIR MAY BE DECREASED. DOSES HAVE NOT BEEN ESTABLISHED FOR THE 2 DRUGS WHEN USED IN COMBINATION. CONCOMITANT USE IS NOT RECOMMENDED.', 'CALCIUM CHANNEL BLOCKERS, DIHYDROPYRIDINE: FELODIPINE, NIFEDIPINE, NICARDIPINE', '\xe2\x86\x91 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS', 'PLASMA CONCENTRATIONS OF DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS MAY INCREASE WHEN ADMINISTERED WITH VICTRELIS. CAUTION IS WARRANTED AND CLINICAL MONITORING IS RECOMMENDED.', 'CORTICOSTEROID, SYSTEMIC: DEXAMETHASONE', '\xe2\x86\x93 BOCEPREVIR', 'COADMINISTRATION OF VICTRELIS WITH CYP3A4/5 INDUCERS MAY DECREASE PLASMA CONCENTRATIONS OF BOCEPREVIR, WHICH MAY RESULT IN LOSS OF THERAPEUTIC EFFECT. THEREFORE, THIS COMBINATION SHOULD BE AVOIDED IF POSSIBLE AND USED WITH CAUTION IF NECESSARY.', 'PREDNISONE', '\xe2\x86\x91 PREDNISONE', 'CONCENTRATIONS OF PREDNISONE AND ITS ACTIVE METABOLITE, PREDNISOLONE, INCREASED WHEN ADMINISTERED WITH VICTRELIS [SEE CLINICAL PHARMACOLOGY (12.3) ] . NO DOSE ADJUSTMENT OF PREDNISONE IS NECESSARY WHEN CO-ADMINISTERED WITH VICTRELIS. PATIENTS RECEIVING PREDNISONE AND VICTRELIS SHOULD BE MONITORED APPROPRIATELY.', 'CORTICOSTEROID, INHALED: BUDESONIDE, FLUTICASONE', '\xe2\x86\x91 BUDESONIDE \xe2\x86\x91 FLUTICASONE', 'CONCOMITANT USE OF INHALED BUDESONIDE OR FLUTICASONE WITH VICTRELIS MAY RESULT IN INCREASED PLASMA CONCENTRATIONS OF BUDESONIDE OR FLUTICASONE, RESULTING IN SIGNIFICANTLY REDUCED SERUM CORTISOL CONCENTRATIONS. AVOID COADMINISTRATION IF POSSIBLE, PARTICULARLY FOR EXTENDED DURATIONS.', 'ENDOTHELIN RECEPTOR ANTAGONIST: BOSENTAN', '\xe2\x86\x91 BOSENTAN', 'CONCENTRATIONS OF BOSENTAN MAY BE INCREASED WHEN COADMINISTERED WITH VICTRELIS. USE WITH CAUTION AND MONITOR CLOSELY.', 'HIV INTEGRASE INHIBITOR: RALTEGRAVIR', '\xe2\x86\x94 RALTEGRAVIR', 'NO DOSE ADJUSTMENT REQUIRED FOR VICTRELIS OR RALTEGRAVIR.', 'HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: EFAVIRENZ', '\xe2\x86\x93 BOCEPREVIR', 'PLASMA TROUGH CONCENTRATIONS OF BOCEPREVIR WERE DECREASED WHEN VICTRELIS WAS COADMINISTERED WITH EFAVIRENZ, WHICH MAY RESULT IN LOSS OF THERAPEUTIC EFFECT. AVOID COMBINATION.', 'ETRAVIRINE', '\xe2\x86\x93 ETRAVIRINE', 'CONCENTRATIONS OF ETRAVIRINE DECREASED WHEN COADMINISTERED WITH VICTRELIS. THE CLINICAL SIGNIFICANCE OF THE REDUCTIONS IN ETRAVIRINE PHARMACOKINETIC PARAMETERS HAS NOT BEEN DIRECTLY ASSESSED.', 'HIV PROTEASE INHIBITORS: ATAZANAVIR/RITONAVIR', '\xe2\x86\x93 ATAZANAVIR \xe2\x86\x93 RITONAVIR', 'CONCOMITANT ADMINISTRATION OF BOCEPREVIR AND ATAZANAVIR/RITONAVIR RESULTED IN REDUCED STEADY-STATE EXPOSURES TO ATAZANAVIR AND RITONAVIR. COADMINISTRATION OF ATAZANAVIR/RITONAVIR AND BOCEPREVIR IS NOT RECOMMENDED.', 'DARUNAVIR/RITONAVIR', '\xe2\x86\x93 DARUNAVIR \xe2\x86\x93 RITONAVIR \xe2\x86\x93 BOCEPREVIR', 'CONCOMITANT ADMINISTRATION OF BOCEPREVIR AND DARUNAVIR/RITONAVIR RESULTED IN REDUCED STEADY-STATE EXPOSURES TO BOCEPREVIR, DARUNAVIR AND RITONAVIR. COADMINISTRATION OF DARUNAVIR/RITONAVIR AND BOCEPREVIR IS NOT RECOMMENDED.', 'LOPINAVIR/RITONAVIR', '\xe2\x86\x93 LOPINAVIR \xe2\x86\x93 RITONAVIR \xe2\x86\x93 BOCEPREVIR', 'CONCOMITANT ADMINISTRATION OF BOCEPREVIR AND LOPINAVIR/RITONAVIR RESULTED IN REDUCED STEADY-STATE EXPOSURES TO BOCEPREVIR, LOPINAVIR AND RITONAVIR. COADMINISTRATION OF LOPINAVIR/RITONAVIR AND BOCEPREVIR IS NOT RECOMMENDED.', 'RITONAVIR', '\xe2\x86\x93 BOCEPREVIR', 'WHEN BOCEPREVIR IS ADMINISTERED WITH RITONAVIR ALONE, BOCEPREVIR CONCENTRATIONS ARE DECREASED.', 'HMG-COA REDUCTASE INHIBITORS: ATORVASTATIN', '\xe2\x86\x91 ATORVASTATIN', 'EXPOSURE TO ATORVASTATIN WAS INCREASED WHEN ADMINISTERED WITH VICTRELIS. USE THE LOWEST EFFECTIVE DOSE OF ATORVASTATIN, BUT DO NOT EXCEED A DAILY DOSE OF 40 MG WHEN COADMINISTERED WITH VICTRELIS.', 'PRAVASTATIN', '\xe2\x86\x91 PRAVASTATIN', 'CONCOMITANT ADMINISTRATION OF PRAVASTATIN WITH VICTRELIS INCREASED EXPOSURE TO PRAVASTATIN. TREATMENT WITH PRAVASTATIN CAN BE INITIATED AT THE RECOMMENDED DOSE WHEN COADMINISTERED WITH VICTRELIS. CLOSE CLINICAL MONITORING IS WARRANTED.', 'IMMUNOSUPPRESSANTS: CYCLOSPORINE TACROLIMUS SIROLIMUS', '\xe2\x86\x91CYCLOSPORINE', 'DOSE ADJUSTMENTS OF CYCLOSPORINE SHOULD BE ANTICIPATED WHEN ADMINISTERED WITH VICTRELIS AND SHOULD BE GUIDED BY CLOSE MONITORING OF CYCLOSPORINE BLOOD CONCENTRATIONS, AND FREQUENT ASSESSMENTS OF RENAL FUNCTION AND CYCLOSPORINE-RELATED SIDE EFFECTS.', '', '\xe2\x86\x91TACROLIMUS', 'CONCOMITANT ADMINISTRATION OF VICTRELIS WITH TACROLIMUS REQUIRES SIGNIFICANT DOSE REDUCTION AND PROLONGATION OF THE DOSING INTERVAL FOR TACROLIMUS, WITH CLOSE MONITORING OF TACROLIMUS BLOOD CONCENTRATIONS AND FREQUENT ASSESSMENTS OF RENAL FUNCTION AND TACROLIMUS-RELATED SIDE EFFECTS.', '', '\xe2\x86\x91SIROLIMUS', 'BLOOD CONCENTRATIONS OF SIROLIMUS ARE EXPECTED TO INCREASE SIGNIFICANTLY WHEN ADMINISTERED WITH VICTRELIS. CLOSE MONITORING OF SIROLIMUS BLOOD LEVELS IS RECOMMENDED.', 'INHALED BETA-AGONIST: SALMETEROL', '\xe2\x86\x91 SALMETEROL', 'CONCURRENT USE OF INHALED SALMETEROL AND VICTRELIS IS NOT RECOMMENDED DUE TO THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH SALMETEROL.', 'NARCOTIC ANALGESIC/OPIOID DEPENDENCE: METHADONE', '\xe2\x86\x93 R-METHADONE', 'PLASMA CONCENTRATIONS OF R -METHADONE DECREASED WHEN COADMINISTERED WITH VICTRELIS [SEE CLINICAL PHARMACOLOGY (12.3) ] . THE OBSERVED CHANGES ARE NOT CONSIDERED CLINICALLY RELEVANT. NO DOSE ADJUSTMENT OF METHADONE OR VICTRELIS IS RECOMMENDED. INDIVIDUAL PATIENTS MAY REQUIRE ADDITIONAL TITRATION OF THEIR METHADONE DOSAGE WHEN VICTRELIS IS STARTED OR STOPPED TO ENSURE CLINICAL EFFECT OF METHADONE.', 'BUPRENORPHINE/NALOXONE', '\xe2\x86\x91 BUPRENORPHINE/NALOXONE', 'PLASMA CONCENTRATIONS OF BUPRENORPHINE AND NALOXONE INCREASED WHEN COADMINISTERED WITH VICTRELIS [SEE CLINICAL PHARMACOLOGY (12.3) ] . THE OBSERVED CHANGES ARE NOT CONSIDERED CLINICALLY RELEVANT. NO DOSE ADJUSTMENT OF BUPRENORPHINE/NALOXONE OR VICTRELIS IS RECOMMENDED.', 'ORAL HORMONAL CONTRACEPTIVES: DROSPIRENONE/ETHINYL ESTRADIOL', '\xe2\x86\x91 DROSPIRENONE \xe2\x86\x93 ETHINYL ESTRADIOL', 'CONCENTRATIONS OF DROSPIRENONE INCREASED IN THE PRESENCE OF BOCEPREVIR. THUS, THE USE OF DROSPIRENONE-CONTAINING PRODUCTS IS CONTRAINDICATED DURING TREATMENT WITH VICTRELIS DUE TO POTENTIAL FOR HYPERKALEMIA [SEE CONTRAINDICATIONS (4) ] .', 'NORETHINDRONE/ETHINYL ESTRADIOL', '\xe2\x86\x93 ETHINYL ESTRADIOL \xe2\x86\x94 NORETHINDRONE', 'CONCENTRATIONS OF ETHINYL ESTRADIOL DECREASED IN THE PRESENCE OF BOCEPREVIR. NORETHINDRONE C MAX DECREASED 17% IN THE PRESENCE OF BOCEPREVIR [SEE CLINICAL PHARMACOLOGY (12.3) ] . COADMINISTRATION OF VICTRELIS WITH A COMBINED ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND AT LEAST 1 MG OF NORETHINDRONE IS NOT LIKELY TO ALTER THE EFFECTIVENESS OF THIS COMBINED ORAL CONTRACEPTIVE [SEE USE IN SPECIFIC POPULATIONS (8.1) ]. PATIENTS USING ESTROGENS AS HORMONE REPLACEMENT THERAPY SHOULD BE CLINICALLY MONITORED FOR SIGNS OF ESTROGEN DEFICIENCY.', 'PDE5 INHIBITORS: SILDENAFIL, TADALAFIL, VARDENAFIL', '\xe2\x86\x91 SILDENAFIL \xe2\x86\x91 TADALAFIL \xe2\x86\x91 VARDENAFIL', 'INCREASES IN PDE5 INHIBITOR CONCENTRATIONS ARE EXPECTED, AND MAY RESULT IN AN INCREASE IN ADVERSE EVENTS, INCLUDING HYPOTENSION, SYNCOPE, VISUAL DISTURBANCES, AND PRIAPISM. USE OF REVATIO \xc2\xae (SILDENAFIL) OR ADCIRCA \xc2\xae (TADALAFIL) FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IS CONTRAINDICATED WITH VICTRELIS [SEE CONTRAINDICATIONS (4) ]. USE OF PDE5 INHIBITORS FOR ERECTILE DYSFUNCTION: USE WITH CAUTION IN COMBINATION WITH VICTRELIS WITH INCREASED MONITORING FOR PDE5 INHIBITOR-ASSOCIATED ADVERSE EVENTS. DO NOT EXCEED THE FOLLOWING DOSES: SILDENAFIL: 25 MG EVERY 48 HOURS TADALAFIL: 10 MG EVERY 72 HOURS VARDENAFIL: 2.5 MG EVERY 24 HOURS', 'PROTON PUMP INHIBITOR: OMEPRAZOLE', '\xe2\x86\x94 OMEPRAZOLE', 'NO DOSE ADJUSTMENT OF OMEPRAZOLE OR VICTRELIS IS RECOMMENDED.', 'SEDATIVE/HYPNOTICS: ALPRAZOLAM; IV MIDAZOLAM', '\xe2\x86\x91 MIDAZOLAM \xe2\x86\x91 ALPRAZOLAM', 'CLOSE CLINICAL MONITORING FOR RESPIRATORY DEPRESSION AND/OR PROLONGED SEDATION SHOULD BE EXERCISED DURING COADMINISTRATION OF VICTRELIS. A LOWER DOSE OF IV MIDAZOLAM OR ALPRAZOLAM SHOULD BE CONSIDERED.']